|
|
Prepublished online as a Blood First Edition Paper on May 1, 2003; DOI 10.1182/blood-2003-03-0744.
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2003, Vol. 102, No. 5, pp. 1869-1871
NEOPLASIA
Brief report
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders
Robert Kralovics,
Andreas S. Buser,
Soon-Siong Teo,
Jörn Coers,
Andre Tichelli,
Anthonie P. C. van der Maas, and
Radek C. Skoda
From the Department of Research, Division of Hematology and Department of
Laboratory Medicine, Basel University Hospital, Switzerland; and the
Department of Internal Medicine, Medical Centre Haaglanden, The Hague, The
Netherlands.
Decreased expression of c-MPL protein in platelets, increased expression of
polycythemia rubra vera 1 (PRV-1) and nuclear factor I-B (NFIB) mRNA in
granulocytes, and loss of heterozygosity on chromosome 9p (9pLOH) were
described as molecular markers for myeloproliferative disorders (MPDs). To
assess whether these markers are clustered in subgroups of MPDs or represent
independent phenotypic variations, we simultaneously determined their status
in a cohort of MPD patients. Growth of erythropoietin-independent colonies
(EECs) was measured for comparison. We observed concordance between EECs and
PRV-1 in MPD patients across all diagnostic subclasses, but our results
indicate that EECs remain the most reliable auxiliary test for polycythemia
vera (PV). In contrast, c-MPL, NFIB, and 9pLOH constitute independent
variations. Interestingly, decreased c-MPL and elevated PRV-1 also were
observed in patients with hereditary thrombocythemia (HT) who carry a mutation
in the thrombopoietin (TPO) gene. Thus, altered c-MPL and PRV-1 expression
also can arise through a molecular mechanism different from sporadic MPD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. X. Schaub, R. Jager, R. Looser, H. Hao-Shen, S. Hermouet, F. Girodon, A. Tichelli, H. Gisslinger, R. Kralovics, and R. C. Skoda
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
Blood,
February 26, 2009;
113(9):
2022 - 2027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tiedt, J. Coers, S. Ziegler, A. Wiestner, H. Hao-Shen, C. Bornmann, J. Schenkel, S. Karakhanova, F. J. de Sauvage, C. W. Jackson, et al.
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes
Blood,
February 19, 2009;
113(8):
1768 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Liu, R. Kralovics, Z. Rudzki, B. Grabowska, A. S. Buser, D. Olcaydu, H. Gisslinger, R. Tiedt, P. Frank, K. Okon, et al.
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family
Haematologica,
May 1, 2008;
93(5):
706 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Blood,
April 15, 2008;
111(8):
3931 - 3940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Blood,
April 1, 2008;
111(7):
3863 - 3866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bauer, M. Abdgawad, L. Gunnarsson, M. Segelmark, H. Tapper, and T. Hellmark
Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils
J. Leukoc. Biol.,
February 1, 2007;
81(2):
458 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology,
January 1, 2007;
2007(1):
1 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2006;
8(4):
397 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kralovics, S.-S. Teo, S. Li, A. Theocharides, A. S. Buser, A. Tichelli, and R. C. Skoda
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Blood,
August 15, 2006;
108(4):
1377 - 1380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bock, G. Busche, C. Koop, S. Schroter, T. Buhr, and H. Kreipe
Detection of the Single Hotspot Mutation in the JH2 Pseudokinase Domain of Janus Kinase 2 in Bone Marrow Trephine Biopsies Derived from Chronic Myeloproliferative Disorders
J. Mol. Diagn.,
May 1, 2006;
8(2):
170 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kralovics, S.-S. Teo, A. S. Buser, M. Brutsche, R. Tiedt, A. Tichelli, F. Passamonti, D. Pietra, M. Cazzola, and R. C. Skoda
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Blood,
November 15, 2005;
106(10):
3374 - 3376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Goerttler, C. Steimle, E. Marz, P. L. Johansson, B. Andreasson, M. Griesshammer, H. Gisslinger, H. Heimpel, and H. L. Pahl
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients
Blood,
October 15, 2005;
106(8):
2862 - 2864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A. J. Chase, F. H. Grand, et al.
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Blood,
September 15, 2005;
106(6):
2162 - 2168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc.,
July 1, 2005;
80(7):
947 - 958.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Kralovics, F. Passamonti, A. S. Buser, S.-S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, and R. C. Skoda
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
N. Engl. J. Med.,
April 28, 2005;
352(17):
1779 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell and A. R. Green
Management of Polycythemia Vera and Essential Thrombocythemia
Hematology,
January 1, 2005;
2005(1):
201 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Teofili, M. Martini, F. Guidi, D. Venditti, G. Leone, and M. L. Larocca
The PRV-1 gene expression in essential thrombocythemia
Blood,
November 1, 2004;
104(9):
2995 - 2996.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Coers, C. Ranft, and R. C. Skoda
A Truncated Isoform of c-Mpl with an Essential C-terminal Peptide Targets the Full-length Receptor for Degradation
J. Biol. Chem.,
August 27, 2004;
279(35):
36397 - 36404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Schomber, C. P. Kalberer, A. Wodnar-Filipowicz, and R. C. Skoda
Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells
Blood,
June 15, 2004;
103(12):
4511 - 4513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, T. L. Lasho, A. P. Wolanskyj, and R. A. Mesa
Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia
Blood,
May 1, 2004;
103(9):
3547 - 3548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Florensa, C. Besses, L. Zamora, B. Bellosillo, B. Espinet, S. Serrano, S. Woessner, and F. Sole
Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia
Blood,
March 15, 2004;
103(6):
2427 - 2428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cilloni, S. Carturan, E. Gottardi, F. Messa, M. Fava, I. Defilippi, F. Arruga, G. Saglio, S. Klippel, P. S. Goerttler, et al.
Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients
Blood,
March 15, 2004;
103(6):
2428 - 2429.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Palmqvist, P. Goerttler, C. Wasslavik, P. Johansson, B. Andreasson, S. Safai-Kutti, J. Kutti, H. L. Pahl, and A. Ricksten
Comparison of Methods for Polycythemia Rubra Vera-1 mRNA Quantification in Whole-Blood Leukocytes and Purified Granulocytes
Clin. Chem.,
March 1, 2004;
50(3):
644 - 647.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Prchal and J. T. Prchal
A specific test for polycythemia vera?
Blood,
November 15, 2003;
102(10):
3464 - 3464.
[Full Text]
[PDF]
|
|
|
|
|
